Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.
Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Dogs Are Forced To Wear The Things They Steal — And It’s Hilarious
Meet Nazgul: The Dog Who Crashed An Olympic Ski Race And Nearly Won
She Collects Trash 5 Days A Week With Her Dog — So A Resident Gifted Her Dog A Matching Vest
She Was Feeling Low On Confidence, So Her Classmates Covered Her Desk In Sticky Notes
A Childhood Bond Reunited: Firefighter Saves The Horse That Taught Him To Ride
This Baby Giraffe Named Eugene Was Born With The Most Hilarious Tuft Of Hair You’ve Ever Seen
Reporter Asks Eileen Gu 'Do You Think Before You Speak?' — Her Answer Is Going Viral
Son Stops Mid Race To Give His Mom A Kiss During The Special Olympics
He Went Back To Pay The Man Who Helped Him — But That’s Not What Happened
A Mom Saw A Soldier Who Didn't Have Any Family... So She Hugged Him
Man Helps Distressed Swan Find Her Way Back To The River
